ReviewJournal of translational internal medicine2021
The challenges and optimization of cell-based therapy for cardiovascular disease.
Review in Journal of translational internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Stratifying cardiometabolic risk in urban Chinese children with obesity: Study protocol of the Shenzhen Children Cohort Study (SCCS).PloS one · 2026Article
- Unveiling the shared etiology between gastrointestinal disorders and valvular heart diseases through a genome-wide pleiotropy study.NPJ cardiovascular health · 2025Article
- The intersection of ferroptosis and non-coding RNAs: a novel approach to ovarian cancer.European journal of medical research · 2025Review
- Review
- Exosomes-mediated drug delivery for the treatment of myocardial injury.Annals of medicine and surgery (2012) · 2024Review
- Effects of time-restricted eating with different eating windows on human metabolic health: pooled analysis of existing cohorts.Diabetology & metabolic syndrome · 2023Article
- Evolving Clinical-Translational Investigations of Cerebroprotection in Ischemic Stroke.Journal of clinical medicine · 2023Review
- Treatment of Cardiac Fibrosis with Extracellular Vesicles: What Is Missing for Clinical Translation?International journal of molecular sciences · 2023Review
- Can Extracellular Vesicles as Drug Delivery Systems Be a Game Changer in Cardiac Disease?Pharmaceutical research · 2023Review
- Stem cell- derived extracellular vesicles as new tools in regenerative medicine - Immunomodulatory role and future perspectives.Frontiers in immunology · 2023Review
- Development and validation of risk prediction and neural network models for dilated cardiomyopathy based on WGCNA.Frontiers in medicine · 2023Article
- Research Progress on NJournal of translational internal medicine · 2022Article
- Extracellular Vesicles in Cardiovascular Diseases: Diagnosis and Therapy.Frontiers in cell and developmental biology · 2022Review
- The role of microRNAs in ferroptosis.Frontiers in molecular biosciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the hope of achieving real cardiovascular repair, cell-based therapy raised as a promising strategy for the treatment of cardiovascular disease (CVD) in the past two decades. Various types of cells have been studied for their reparative potential for CVD in the ensuing years. Despite the exciting results from animal experiments, the outcome of clinical trials is unsatisfactory and the development of cell-based therapy for CVD has hit a plateau nowadays. Thus, it is important to summarize the obstacles we are facing in this field in order to explore possible solutions for optimizing cell-based therapy and achieving real clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.